Medicare must review drug coverage denials in 120 days.
H.R. 9418 — Access to Innovative Treatments Act of 2026 · Filed by Nanette Barragán (D-CA) · 1 cosponsor · Introduced Jun 24, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
The bill creates a fast review process for drug denials. Medicare must decide within 120 days and explain why. The bill stops Medicare from using old denials for new drugs. If Medicare says yes, it must share the medical evidence.
Who it affects
Patients may get faster access to new drugs. Drug makers can request reviews of Medicare's no decisions. Medicare and insurance plans will follow new rules.
One thing to notice
The bill requires a decision in 120 days. The bill does not say who can ask for review.
From the analysis of the bill text, linked under Primary records below.
Where it stands
1 cosponsor: 1 Republicans.
- Jun 24, 2026 — Introduced · Congress.gov: “Introduced in House”
- Jun 24, 2026 — Referred to House Committee on Energy and Commerce and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
2 groups reported lobbying about this bill. They filed 2 reports from Jun 2026 to Jun 2026.
Those reports show $1,930,000 in lobbying spending. Each report lists about 22 bills. So that money was not all for this bill.
More groups named this bill than 41% of bills with any report.
Nanette Barragán, who sponsored the bill, received $661,800 from PACs for the 2026 election.
- Alzheimer's Association — $1,800,000 in 1 report
- Usagainstalzheimers Action — $130,000 in 1 report
Lobbying is legal. These reports show who lobbied about this bill, not what changed.
Words to know
- Medicare — A federal health insurance program for people age 65 and older.
- coverage — When an insurance plan agrees to pay for a drug or treatment.
- denials — Times when Medicare says no to paying for a drug.
- lobbying — Trying to influence lawmakers about a bill. Companies and groups pay people to do this.
- PACs — Groups that collect money and give it to candidates for office.
- sponsored — To sponsor a bill is to introduce it in Congress and put your name on it.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (4,077 characters) on Aug 12, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 14,206 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-09-17.
“Medicare must review drug coverage denials in 120 days.” QuorumCivic. https://share.quorumcivic.app/bill/119/hr9418/simple Report an error